INSMED INC Increase (Decrease) in Employee Related Liabilities
INSMED INC (INSM) reported Increase (Decrease) in Employee Related Liabilities of -$5.57 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2021-10-28
- INSMED INC increase (decrease) in employee related liabilities for the quarter ending 2021-09-30 was $3.76M, a 23.24% increase year-over-year.
- INSMED INC increase (decrease) in employee related liabilities for the quarter ending 2021-06-30 was $5.78M, a 41.94% increase year-over-year.
- INSMED INC increase (decrease) in employee related liabilities for the quarter ending 2021-03-31 was -$15.11M.
- INSMED INC increase (decrease) in employee related liabilities for the quarter ending 2020-12-31 was $8.85M, a 70.63% increase year-over-year.
- INSMED INC increase (decrease) in employee related liabilities for fiscal 2020 was $5.78M.
- INSMED INC increase (decrease) in employee related liabilities for fiscal 2019 was -$3.07M, a 130.65% decline from fiscal 2018.
- INSMED INC increase (decrease) in employee related liabilities for fiscal 2018 was $10.01M, a 90.32% increase from fiscal 2017.
- INSMED INC increase (decrease) in employee related liabilities for fiscal 2017 was $5.26M, a 99.62% increase from fiscal 2016.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2021-09-30 | $3.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $9.54M derived: sum of 2 quarters · filed 2021-10-28 | -$5.57M 10-Q · filed 2021-10-28 | $3.28M derived: sum of 4 quarters · filed 2021-10-28 |
| 2021-06-30 | $5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$9.33M 10-Q · filed 2021-08-05 | -$478.00K derived: sum of 3 quarters · filed 2021-08-05 | $2.57M derived: sum of 4 quarters · filed 2021-10-28 |
| 2021-03-31 | -$15.11M 10-Q · filed 2021-05-06 | -$6.26M derived: sum of 2 quarters · filed 2021-05-06 | -$3.21M derived: sum of 3 quarters · filed 2021-10-28 | $865.00K derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-12-31 | $8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $11.90M derived: sum of 2 quarters · filed 2021-10-28 | $15.97M derived: sum of 3 quarters · filed 2021-10-28 | $5.78M 10-K · filed 2021-02-25 |
| 2020-09-30 | $3.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $7.12M derived: sum of 2 quarters · filed 2021-10-28 | -$3.07M 10-Q · filed 2021-10-28 | $2.12M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$6.12M 10-Q · filed 2021-08-05 | -$933.00K derived: sum of 3 quarters · filed 2021-08-05 | $2.80M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$10.19M 10-Q · filed 2021-05-06 | -$5.00M derived: sum of 2 quarters · filed 2021-05-06 | -$1.27M derived: sum of 3 quarters · filed 2021-05-06 | -$7.32M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $5.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.92M derived: sum of 2 quarters · filed 2021-02-25 | $2.87M derived: sum of 3 quarters · filed 2021-02-25 | -$3.07M 10-K · filed 2021-02-25 |
| 2019-09-30 | $3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$2.32M derived: sum of 2 quarters · filed 2020-10-29 | -$8.25M 10-Q · filed 2020-10-29 | $2.57M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$11.99M 10-Q · filed 2020-08-06 | -$1.17M derived: sum of 3 quarters · filed 2021-02-25 | $2.85M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$5.94M 10-Q · filed 2020-04-30 | $4.88M derived: sum of 2 quarters · filed 2021-02-25 | $8.90M derived: sum of 3 quarters · filed 2021-02-25 | $11.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $10.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $14.84M derived: sum of 2 quarters · filed 2021-02-25 | $17.71M derived: sum of 3 quarters · filed 2021-02-25 | $10.01M 10-K · filed 2021-02-25 |
| 2018-09-30 | $4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $6.89M derived: sum of 2 quarters · filed 2019-10-30 | -$810.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$4.83M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | -$7.70M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $5.26M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $2.63M 10-K · filed 2019-02-22 | |||
| 2015-06-30 | $966.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$1.77M 10-Q · filed 2015-08-06 | -$481.00K derived: sum of 3 quarters · filed 2015-08-06 | $479.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | -$2.73M 10-Q · filed 2015-05-07 | -$1.45M derived: sum of 2 quarters · filed 2015-05-07 | -$487.00K derived: sum of 3 quarters · filed 2015-05-07 | $213.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $2.25M derived: sum of 2 quarters · filed 2015-02-27 | $2.95M derived: sum of 3 quarters · filed 2015-08-06 | $1.48M 10-K · filed 2015-02-27 |
| 2014-09-30 | $960.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.66M derived: sum of 2 quarters · filed 2015-08-06 | $192.00K 10-Q · filed 2014-11-06 | $1.08M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$768.00K 10-Q · filed 2015-08-06 | $118.00K derived: sum of 3 quarters · filed 2015-08-06 | $182.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | -$1.47M 10-Q · filed 2015-05-07 | -$582.00K derived: sum of 2 quarters · filed 2015-05-07 | -$518.00K derived: sum of 3 quarters · filed 2015-05-07 | $12.00K derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $886.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $950.00K derived: sum of 2 quarters · filed 2015-02-27 | $1.48M derived: sum of 3 quarters · filed 2015-02-27 | $632.00K 10-K · filed 2015-02-27 |
| 2013-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $594.00K derived: sum of 2 quarters · filed 2014-11-06 | -$254.00K 10-Q · filed 2014-11-06 | $372.00K derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$318.00K 10-Q · filed 2014-08-06 | $308.00K derived: sum of 3 quarters · filed 2015-02-27 | $1.04M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | -$848.00K 10-Q · filed 2014-05-08 | -$222.00K derived: sum of 2 quarters · filed 2015-02-27 | $510.00K derived: sum of 3 quarters · filed 2015-02-27 | $849.00K derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $626.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $1.36M derived: sum of 2 quarters · filed 2015-02-27 | $1.70M derived: sum of 3 quarters · filed 2015-02-27 | $1.41M 10-K · filed 2015-02-27 |
| 2012-09-30 | $732.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $1.07M derived: sum of 2 quarters · filed 2013-11-05 | $786.00K 10-Q · filed 2013-11-05 | |
| 2012-06-30 | $339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $54.00K 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | -$285.00K 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | -$322.00K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |